Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
Journal Title
Acta Pharmaceutica Sinica B
Publication Type
Journal epub ahead of print
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with Corona Virus Disease 2019 (COVID-19), we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. Food and Drug Administration (FDA) approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P<0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.
Publisher
Elsevier
WEHI Research Division(s)
Immunology
PubMed ID
32318327
Open Access at Publisher's Site
https://doi.org/10.1016/j.apsb.2020.04.008
NHMRC Grants
NHMRC/1080321 NHMRC/1143976 NHMRC/1150425
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2020-05-04 10:30:34
Last Modified: 2020-05-04 10:50:07
An error has occurred. This application may no longer respond until reloaded. Reload 🗙